Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation
Status:
Completed
Trial end date:
2018-09-24
Target enrollment:
Participant gender:
Summary
There are insufficient data on the safety and efficacy of edoxaban therapy in subjects with
AF following catheter ablation. This phase 3b study is designed to evaluate the safety and to
explore the efficacy of an edoxaban-based antithrombotic regimen versus a VKA-based
antithrombotic regimen in subjects with AF following catheter ablation. Bleeding is a central
safety outcome in cardiovascular clinical trials, especially for antithrombotic strategies
and invasive procedures.
Phase:
Phase 3
Details
Lead Sponsor:
Daiichi Sankyo Europe, GmbH Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company